Evidence map›Paper›PMID 34095175›Full record

ArticleFrontiers in medicine2021

Frequency of Positive Conversion of Interferon-Gamma Release Assay Results Among Patients With Inflammatory Bowel Disease Treated With Non-tumor Necrosis Factor Inhibitors.

Kyuwon Kim, Kyung-Wook Jo, Tae Sun Shim, Jin Hwa Park, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Yield of Serial Testing for Tuberculosis Exposure in Patients With Inflammatory Bowel Diseases: One Test is Not Enough.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Kyuwon KimDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Kyung-Wook JoDepartment of Pulmonology and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Tae Sun ShimDepartment of Pulmonology and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Jin Hwa ParkDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Sung Wook HwangDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Sang Hyoung ParkDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Dong-Hoon YangDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Jeong-Sik ByeonDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Seung-Jae MyungDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Suk-Kyun YangDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Byong Duk YeDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Ulsan College · KRAsan Medical Center · KRUniversity of Ulsan · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Considering the risk of reactivation of latent tuberculosis infection (LTBI), not only before starting tumor necrosis factor inhibitors but also before non-TNF inhibitor therapy, LTBI screening is routinely recommended for patients with inflammatory bowel disease (IBD). However, data on the positive conversion of LTBI test results during non-TNF inhibitor therapy are scarce. Among IBD patients treated with vedolizumab and/or ustekinumab, a total of 91 patients who had negative baseline interferon-gamma release assay (IGRA) results, assessed by QuantiFERON

Indexed as

inflammatory bowel diseaseinterferon-gamma release assaylatent tuberculosis infectionustekinumabvedolizumab

Identifiers

PMID34095175
PMCPMC8175966
OpenAlexW3162184759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.